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Edited by R. HuberAbstractCAPN3/p94/calpain-3 is a skeletal-muscle-specific member of the calpain protease family. Multiple muscle cell
functions have been reported for CAPN3, and mutations in this protease cause limb-girdle muscular dystrophy
type 2A. Little is known about the molecular mechanisms that allow CAPN3 to be so multifunctional. One
hypothesis is that the very rapid and exhaustive autolytic activity of CAPN3 needs to be suppressed by dynamic
molecular interactions for specific periods of time. The previously identified interaction between CAPN3 and
connectin/titin, a giant molecule in muscle sarcomeres, supports this assumption; however, the regulatory
mechanisms of non-sarcomere-associated CAPN3 are unknown. Here, we report that a novel CAPN3-binding
protein, PLEIAD [Platform element for inhibition of autolytic degradation; originally called SIMC1/C5orf25
(SUMO-interactingmotif containing protein 1/chromosome 5 open reading frame 25)], suppresses the protease
activity of CAPN3. Database analyses showed that PLEIAD homologs, like CAPN3 homologs, are evolutionarily
conserved in vertebrates. Furthermore, we found that PLEIAD also interacts with CTBP1 (C-terminal binding
protein 1), a transcriptional co-regulator, and CTBP1 is proteolyzed in COS7 cells expressing CAPN3. The
identified cleavage sites in CTBP1 suggested that it undergoes functional modification upon its proteolysis by
CAPN3, as well as by conventional calpains. These results indicate that PLEIAD can shift its major function from
CAPN3 suppression to CAPN3-substrate recruitment, depending on the cellular context. Taken together, our
data suggest that PLEIAD is a novel regulatory scaffold for CAPN3, as reflected in its name.
© 2013 The Authors. Published by Elsevier Ltd.Open access under CC BY license.IntroductionCAPN3 (also called p94 or calpain-3) is an skm
(skeletal muscle)-specific cysteine protease belong-
ing to the calpain super family (EC 3.4.22.18, clan
CA, family C2).1 The calpains are intracellular Ca2+-
requiring cysteine proteases. Many studies have
shown that proteolysis by calpain has a modulatory
effect on the functions of the substrate proteins.2–6
Therefore, calpain is considered to be a modulator0022-2836 © 2013 The Authors. Published by Elsevier Ltd. Open access protease rather than a degrading protease such as
proteasomal and lysosomal proteases.7
Froma physiological perspective, genetic defects in
CAPN3 cause limb-girdle muscular dystrophy type
2A8; therefore, the importance of CAPN3's functions
are well recognized.9 To examine the consequences
of altering the modulating functions of CAPN3 in skm,
we have generated several different mouse limb-
girdle muscular dystrophy type 2A models, including
knockout mice (Capn3−/−), which lack the full-length
CAPN3 protein10–17; knockin mice (Capn3CS/CS) inJ. Mol. Biol. (2013) 425, 2955–2972under CC BY license.
2956 PLEIAD/SIMC1/C5orf25, a Regulator for CAPN3which CAPN3 is replaced by a protease-inactive
mutant CAPN3:C129S (CAPN3:CS)18,19; and trans-
genic mice in which CAPN3:CS is overexpressed.20
Analyses of these models have shown that CAPN3
has different cellular functions depending on the
subcellular compartment in which it is located. In
particular, a surprising finding was that CAPN3
localizes to triads, where it plays an important role
as a structural component and not as a protease.19
The two defined roles of CAPN3, that is, as a
protease and as a structural protein, are not neces-
sarily mutually exclusive. However, too little is
currently known about the molecular properties of
CAPN3 to explain the relationships among these two
roles and another property of CAPN3—its very rapid
autolysis.21 In skm cells, CAPN3's stability as a pre-
autolytic full-length molecule has been attributed to its
interaction with connectin/titin, a giant sarcomeric
protein,22,23 since connectin/titin's ability to suppress
the autolytic loss of CAPN3 has been shown
biochemically.24 Furthermore, the N2A region of
connectin/titin has been suggested to function as a
scaffold for CAPN3.25,26 However, in skm cells,
CAPN3 is stable not only in sarcomeres but also in
the cytosol.27 Therefore, it is predicted that there are
other regulatory mechanisms working in parallel or in
combinationwith the connectin/titin-basedmachinery,
to support CAPN3's multiple functions, especially
those occurring outside of sarcomeres.
We sought to identify CAPN3-interacting proteins
using a highly sensitive and efficientmethod based on
mass spectrometry for analyzing protein–protein
interactions.28 Among these proteins, PLEIAD (Plat-
form element for inhibition of autolytic degradation),
which was the previously uncharacterized SIMC1/
C5orf25 (SUMO-interactingmotif containing protein 1/
chromosome 5 open reading frame 25),29 demon-Fig. 1. A novel human protein, PLEIAD/C5orf25, interacts
schematically shown. Autolytic activity is based on the result
arrows indicate predominant autolytic sites. PC1 and PC2, prot
penta-EF-hand; NS/IS1/IS2, CAPN3-specific insertion sequenc
His, and Asn; CAPN3:CS, protease-inactive mutant; CAPN3:N
structure of hPLEIAD and its genomic structure. Transcript
summarized in Table 2. hPLEIADa to e, known splicing variants
in this study, which lacks exons 2 and 3. “S1” to “S3” and “AS1
primers, respectively, used in the study. The sequences are s
region, respectively; PEST, a region rich in Pro, Glu, Ser, and T
phosphorylation sites are identified in hPLEIAD, S651 and S79
CAPN3:CS(CS) in COS7 cells and immunoprecipitated by ant
coimmunoprecipitated with hPLEIADf. Note that the full-length
expressed alone (lane 1, anti-pIS2). In the presence of coex
appeared to be coimmunoprecipitated more efficiently than th
coexpressed with PLEIADa or hPLEIADf in COS7 cells, the int
to that of the 55-kDa autolyzed fragment increased (lanes 4 an
proteolyzed fragment of fodrin was suppressed (lanes 4 a
expression plasmid for hPLEIADf was reduced, the effects w
observed (lane 6). Closed and open arrowheads indicate the f
detected by Western blotting using an anti-pIS2 antibody. (e)
using the intensity of the autolytic 55-kDa band in the same lastrated a suppressive effect on CAPN3's protease
activity. We identified vertebrate orthologs of PLEIAD
according to their similarity with the human C-terminal
sequence, which harbors the CAPN3 inhibitory or
regulatory activity. We also found that PLEIAD binds
to CTBP1 (C-terminal binding protein 1),30,31 which is
a good substrate for calpains, including CAPN3.
These results suggest that SIMC1/C5orf25 is a
suppressor for CAPN3but, at the same time, scaffolds
CAPN3 to direct and regulate its substrate-proteolyz-
ing activity. Such properties, like those of the
connectin/titin N2A region, would qualify PLEIAD as
an important regulatory protein for CAPN3.
Results
Protease activity of CAPN3 is suppressed by
a novel protein, PLEIAD
To explore molecular interactions relevant to
CAPN3's function and regulation, we expressed
FLAG-CAPN3:N358D (CAPN3:ND), an activity-
attenuated mutant32 (Fig. 1a), in HEK293 cells
and analyzed anti-FLAG coimmunoprecipitates of
HEK293 lysates by liquid chromatography coupled
with tandem mass spectrometry.28 Since the initial
goal was to identify activation-dependent interactions,
the cells were treated with the Ca2+-ionophore
A23187, and the results were compared to those
obtained in cells without A23187 treatment. This
approach identified a novel CAPN3-binding protein
C5orf25, which we named PLEIAD (see below)
(Fig. 1b). To confirm the interaction, we expressed
both proteins in COS7 cells; the interaction between
MYC-PLEIAD and FLAG-CAPN3, as well as the
interaction between FLAG-PLEIAD and CAPN3,with and suppresses CAPN3. (a) Structure of CAPN3 is
when each construct is expressed in COS7 cells. Vertical
ease core domains 1 and 2; C2L, C2-domain-like; PEF (L),
es; C129/H334/N358, active-site amino acid residues Cys,
D, a mutant with attenuated protease activity. (b) Domain
variants are also depicted. The sequence information is
. hPLEIADf, the novel splicing variant of PLEIAD identified
” to “AS4” represent the positions of sense and antisense
ummarized in Table 1. Ser and Pro, Ser-rich and Pro-rich
hr; NLS, putative nuclear localization signal sequence. Two
1. (c) hPLEIADf was coexpressed with CAPN3:WT(WT) or
i-FLAG (FLAG-IP). Both CAPN3:WT and CAPN3:CS were
94-kDa band was hardly detectable when CAPN3:WT was
pressed hPLEIADf, the 94-kDa band became visible and
e 55-kDa autolyzed fragment (lanes 4 and 9). (d) When
ensity of the full-length 94-kDa band of CAPN3:WT relative
d 5, anti-CAPN3). In the same samples, generation of the
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ere smaller, and a decrease in expressed hPLEIADf was
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2958 PLEIAD/SIMC1/C5orf25, a Regulator for CAPN3was reproducible without A23187 treatment (data not
shown). Therefore, A23187 was omitted in the
subsequent experiments.
The human PLEIAD gene (PLEIAD) is composed
of 12 exons, of which exon 3 encodes the canonical
first Met (Fig. 1b). In the National Center for
Biotechnology Information (NCBI) and UniProtKB
databases, the sequences for several alternative
transcripts and corresponding proteins are
deposited.33 None of them, however, contains the
sequence corresponding to exons 2 and 3. By PCR
using a human skm cDNA library, we identified a
novel variant lacking exons 2 and 3, but none of the
other variants was found in the database [Fig. 1b,
(5)]. This isoform will be temporarily designated as
hPLEIADf.
Anti-FLAG coimmunoprecipitation experiments
demonstrated the interaction of FLAG-hPLEIADf
with CAPN3:WT and CAPN3:CS (Fig. 1c, lanes 9
and 10, anti-CAPN3). Therefore, the interaction
between PLEIAD and CAPN3, which was originally
detected in HEK293 cells, is predicted to take place
in skm cells. Notably, the amount of FLAG-hPLEIADf
was decreased when coexpressed with CAPN3:WT
(compare lanes 4 and 5, anti-FLAG), and the relative
intensity of the full-length 94-kDa band of CAPN3:
WT was increased in the same sample (compare
lanes 1 and 4, anti-CAPN3). This phenomenon is
likely to indicate that CAPN3 activity reduces the
amount of PLEIAD, either directly by proteolyzing it
or indirectly by reducing the efficiency of PLEIAD's
expression, and that PLEIAD reduces the autolytic
activity of CAPN3.
These trends were confirmed by several indepen-
dent transfections, and one representative result is
shown in Fig. 1d. The signal intensity of the full-
length 94-kDa band was evaluated using the
intensity of the autolytic 55-kDa band in the same
lane as a standard (Fig. 1e). Both hPLEIADa and
hPLEIADf increased the amount of the 94-kDaFig. 2. The C-terminal region of PLEIAD is responsible for
PLEIAD, hPLEIAD-N [corresponding to exons 1–4, lacking th
additional sequence, LDICCSP, in its C-terminus] and hPLEIA
CAPN3:CS in COS7 cells. PLEIAD homologs identified by p
hPLEIAD-C (Tables 2 and 3). (b) When the C-terminal region, h
WT was visible (lane 3). However, the effect was not as dramat
and 8). Notably, in the same sample, the intensity of the bands
were observed for cells in which CAPN3:CS was coexpressed
open arrowheads indicate the full-length and autolytic fragme
using an anti-pIS2 antibody. (c) Mouse PLEIAD, mPLEIA
4732471D19Rik). In this gene, the exons corresponding to e
largest gene product (mPLEIADa) is composed of 1354 aa, w
structure of mPLEIADb is essentially identical with that of hPLE
(d). The primer sequences are summarized in Table 1. (d) E
splicing variant of CAPN3 without exons 15 and 16 was also fa
template; − and +, isolated total RNA before and after, respectiv
Qc, quadriceps from a 30-week-old mouse; Mt5, myotubes
myoblasts. Expected product sizes for Capn3 (by primers CAP
and 492 bp, respectively.CAPN3:WT, which was dependent on the level of
hPLEIADf (lanes 4, 6, and 8, anti-CAPN3). Since the
CAPN3-dependent proteolysis of fodrin was also
suppressed (lanes 4 and 8 compared with lane 2,
anti-proteolyzed fodrin), it was concluded that the
protease activity of CAPN3 is suppressed by
PLEIAD. Multiple bands were observed for
hPLEIADa and hPLEIADf (Fig. 1d, lanes 4, 5, 8,
and 9), independent of CAPN3's protease activity.
Since FLAG tags were introduced to the N-termini of
the hPLEIADs, the observed molecular sizes of these
bands suggested that the region encoded by exon 4
is susceptible to nonspecific proteolysis in the cell.
The C-terminal region of PLEIAD regulates
CAPN3's autolysis
To define the functional domains of PLEIAD with
respect to their effect on CAPN3 autolysis, we
coexpressed two different PLEIAD regions with
CAPN3 in COS7 cells.
When the C-terminal region, designated as
hPLEIAD-C, was coexpressed with CAPN3, the
amount of CAPN3 detected by anti-CAPN3 in-
creased. That is, the relative intensity of the 94-
kDa band of CAPN3:WT increased, indicating
reduced autolytic activity, but not as much as with
the coexpression of hPLEIADa or hPLEIADf (Fig. 2b,
lane 3 versus Fig. 1d, lanes 4 and 8, anti-CAPN3). In
contrast, the N-terminal region of hPLEIAD, called
hPLEIAD-N, had no effect on the expression pattern
or intensity of CAPN3 (lane 4). These findings
suggested that the conserved C-terminal sequence
retained the CAPN3-suppressing activity, although it
was weaker than the suppression exerted by full-
length hPLEIADa and hPLEIADf.
For the mouse PLEIAD ortholog (mPLEIAD,
originally called LOC319719), the structure of its
gene, Pleiad (originally called 4732471D19Rik), is
similar to that of human PLEIAD (Fig. 2c). There are,regulating CAPN3's autolytic activity. (a) Two regions of
e sequence from 368 aa to 458 aa (91 aa) and having an
D-C (exons 5–12) were coexpressed with CAPN3:WT or
si-BLAST search share homology with the sequence of
PLEIAD-C, was coexpressed, the 94-kDa band of CAPN3:
ic as that observed with full-length PLEIAD (Fig. 1d, lanes 4
for autolyzed fragments was increased. The same patterns
with either fragment of PLEIAD (lanes 6 and 7). Closed and
nts of CAPN3, respectively, detected by Western blotting
D/LOC319719, is encoded by Pleiad (originally called
xons 2 and 3 in the human PLEIAD are not defined. The
hich is much larger than any isoforms of hPLEIAD. The
IADc. S3 and AS2 indicate the position of primers used in
xpression of Pleiad detected by RT-PCR. In myotubes, a
intly detected (lane 11, lower band). W, H2O was used as a
ely, the RT reaction, was used as template; M, size marker.
developed for 5 days from a primary culture of mouse
N3_411 and 412) and Pleiad (S3 and AS2) were 547 bp
2959PLEIAD/SIMC1/C5orf25, a Regulator for CAPN3however, two markedly different features: the exons
corresponding to human exons 2 and 3 are not
identifiable, and exon 2, which by definition corre-(c)
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Table 1. Primers used in this study for cDNA cloning and RT-PCR detection
Primer Reference sequence no. Positiona Sequence
S1 BC037298 143–159s cggtcggtaCCCGyAGCCATGGAGGAb
S2 417–439s aacacatATGGCACCAGCATCTGCTTCTGGb
S3c 2071–2090s TCACCTATGTCATGGAGGAA
AS1 3065–3048as GGAGAGAGAGTTCAGGAGG
AS2c 2545–2562as GGTGGCTTTCCATGGTAG
AS3 2155–2170as AGGGTCTGCTGAAAGT
AS4 739–759as GGTCCAAATCTACAGGATCAC
CAPN3_411 NM_000070.2 1801–1820s CTCTT CACCA TTGGC TTCGC,
CAPN3_412 2347–2367as CAGGTCCTTGTGTTTGTTCAC
a s, sense strand (5′ → 3′); as, antisense strand (5′ ← 3′).
b Lowercase letters indicate the sequence added or modified for cloning purposes.
c The sequences of these primers coincide with the corresponding mouse Pleiad sequences and, thus, were also used for amplification
of mouse cDNA.
2960 PLEIAD/SIMC1/C5orf25, a Regulator for CAPN3transcripts encoding the conserved C-terminal re-
gion of mPLEIADa are expressed in mouse skm
cells (Fig. 2d, lanes 6 and 9).
A psi-BLAST homology search of databases using
the human PLEIAD (hPLEIAD) sequence as a seed
revealed significant conservation of the C-terminal
half of hPLEIAD, corresponding approximately to
exons 5–12 (hPLEIAD-C), among vertebrates
(Fig. 2a and Tables 2 and 3). In contrast, the sequence
of the N-terminal half of hPLEIAD, hPLEIAD-N, was
not an efficient seed for retrieving a conserved
structure among vertebrate PLEIAD homologs.
These observations suggest that the regulation of
CAPN3 autolysis was conducted by the C-terminal
region of PLEIAD homologs during evolution.
PLEIAD interacts with CTBP1, a potential
CAPN3 substrate
Yeast two-hybrid (YTH) screening identified
CTBP1 as an interacting protein candidate forTable 2. Amino acid sequences of PLEIAD homologs used in
Species (abbreviation) General name
Homo sapiens (H. s.) Human
Mus musculus (M. m.) Mouse
Bos taurus (B. t.) Bovine
M. domestica (M. d.) Opossum
Gallus gallus (G. g.) Chicken
Taeniopygia guttata (T. g.) Zebra finch
Meleagris gallopavo (M. g.) Turkey XP_003210
Anolis carolinensis (A. c.) Green anole lizard XP_003227
Xenopus tropicalis (X. t.) Western clawed frog XP_00
ENSXE
Oreochromis niloticus (O. n.) Cichlid fish XP_
Tetraodon nigroviridis (T. n.) Puffer fish CAF
Danio rerio (D. r.) Zebra fish XP_001922
a Data were retrieved from NCBI and Ensembl databases.
b Amino acid sequences corresponding to those encoded by exons 5
c The sequence was revised using genomic and EST sequences s
d Gaps were left unfiled in consideration of uncertainty of depositedPLEIAD. CTBP1 is a highly conserved transcription-
al co-repressor, and its structure–function relation-
ships have been well studied (Fig. 3a).34 In addition
to hPLEIADa, which was originally used as a bait
construct for the screening, hPLEIADf also inter-
acted with CTBP1 (data not shown). In contrast to
PLEIAD's effect on CAPN3's autolysis, PLEIAD's N-
terminal region was sufficient for its interaction with
CTBP1 (Fig. 3b, column D).
To characterize the mechanism of the CTBP1–
PLEIAD interaction, weexaminedmutations that have
been shown to abrogate CTBP1's interaction with the
PLDLSmotif in target proteins (Fig. 3b, columns F and
H). Examining two mutants, A52E and V66R, did not
demonstrate the interaction with hPLEIADa,
hPLEIAD-N, or hPLEIADf:ex4term (2F to 4F and 2H
to 4H). Therefore, it is possible that the structure of
CTBP1 critical for its formation of co-repressor
complexes is also involved in its interaction with
PLEIAD. On the other hand, mutations in NAD(H)-
binding domain of CTBP1 caused autoactivation ofthis study
Accession no.a Size (aa)
Homologous
regionb (aa)
Q8NDZ2 872 459–872
NP_795961.3 1354 945–1354
XP_002690456.1 451 44–451
XP_001380898.1 865 461–865
XP_414554.1 646 245–646
XP_002194388.1 605 210–605
405.1c (ENSMGAT00000005306) 433 32–433
968.1c (ENSACAT00000006428) 441 47–441
2938112.1c (NW_003163664,
TT00000064005, EL834443)
587 215–587
003455259.1c (NT_167549) 426 43–426
92416c,d (CAAE01009900) 316 54–316
583.1c (ENSDART00000129265) 770 381–770
–12 (459–872) in the human C5orf25 gene were used for analysis.
hown in parentheses.
genome sequences.
Table 3. Identity and similarity among 12 vertebrate PLEIAD sequences
% Identity Mammals Birds Reptile Amphibian Fish
% Similarity H. s. M. m. B. t. M. d. G. g. T. g. M. g. A. c. X. t. O. n. T. n.a D. r.
H. s. 93.1 92.9 70.4 51.0 47.2 48.8 46.7 41.2 33.2 43.2 36.1
M. m. 99.0 89.7 70.4 51.0 46.9 50.0 46.2 41.0 33.5 35.9 36.6
B. t. 99.5 99.0 69.4 50.2 46.5 49.5 45.9 40.5 33.5 37.5 36.1
M. d. 91.0 91.5 91.0 50.3 47.3 50.5 44.6 38.4 34.3 38.5 34.5
G. g. 84.4 83.9 84.2 84.5 65.9 91.3 50.6 41.1 33.9 35.8 34.0
T. g. 82.0 82.0 81.8 81.8 90.0 66.8 47.0 40.7 33.3 30.3 35.0
M. g. 82.2 83.2 83.2 83.5 98.0 89.8 49.6 41.4 33.9 37.9 35.0
A. c. 79.7 79.4 78.9 81.0 82.0 80.5 82.5 39.7 31.5 33.9 32.6
X. t. 75.0 75.8 75.3 78.0 76.1 76.7 76.1 75.6 31.3 29.0 30.4
O. n. 73.1 73.4 73.4 72.6 70.8 70.5 72.0 70.8 76.5 46.8 53.2
T. n. 77.3 72.6 77.3 74.0 70.5 68.1 72.6 71.4 71.0 79.9 39.5
D. r. 72.8 73.5 72.0 75.5 73.0 74.1 72.9 74.7 79.3 85.8 81.5
Species names are abbreviated as in Table 2.
a The values for the T. nigroviridis sequence are shown in italics since this sequence contains three gaps.
2961PLEIAD/SIMC1/C5orf25, a Regulator for CAPN3the prey plasmid and were not competent for the
analysis using YTH system.
Unlike the interaction between CAPN3 and
PLEIAD, the interaction between CTBP1 and
PLEIAD and/or CAPN3 was not detectable using
protein expression in COS7 cells. To ensure the
presence of excess amount of CTBP1, we per-
formed in vitro cotranslation of PLEIAD and CAPN3:
CS in the presence of CTBP1 using cell-free protein
expression system (Fig. 3c). Both PLEIADa and
PLEIADf together with CTBP1 were coimmunopre-
cipitated by anti-CAPN3 (Fig. 3d, lanes 5 and 7). In
contrast to PLEIAD, the amount of CTBP1 in
immunoprecipitate was very small and the efficiency
was quite low considering its abundant presence in
“Input” (lanes 1–4).
Unexpectedly, the expression of CAPN3:WT in
COS7 cells caused a significant decrease in
endogenous CTBP1 (Fig. 4a, lane 3, gray arrow-
head). This decrease was even more pronounced
when the triple-tagged CTBP1 construct, MYC-
CTBP1-EGFP-FLAG, was coexpressed with
CAPN3:WT (Fig. 4a, lane 1). The detected major
proteolytic fragment size (open arrow), ca 35 kDa,
was larger than that calculated for EGFP with FLAG,
ca 30 kDa, indicating that proteolysis by coex-
pressed CAPN3 occurred within CTBP1 and not in
the tag regions. A splicing variant of mouse CAPN3,
CAPN3:ΔIS1,35 also resulted in the proteolysis of
coexpressed CTBP1 (Fig. 4b, lane 4). As summa-
rized at the bottom of Fig. 4b, the proteolysis of
CTBP1 occurred in parallel with that of other
potential CAPN3 substrates identified in COS7
cells, such as calpastatin and fodrin. The C-terminal
proteolyzed fragment was purified by anti-FLAG
immunoprecipitation, and its N-terminal sequence
was determined to be G410LPPVA by N-terminal
sequencing (Fig. 4b, open arrow; data not shown).Wenext examined if the proteolysis of endogenous
CTBP1 in differentiated mouse skm primary cultured
cells was induced upon the activation of CAPN3 by
ouabain treatment, which increases the intracellular
Na+ and (indirectly) Ca2+ concentrations.32 The
result was under our detection level (Fig. 4c, lane
2), suggesting that, unlike CAPN3 expressed in
COS7 cells, substrate proteolysis by endogenous
CAPN3 in skm is still tightly regulated even when its
autolysis is detectable and/or the proteolysis of
endogenous CTBP1 does not occur at a level that
is artificially induced by CAPN3 overexpression in
COS7 cells.
The effect of missense mutations that have been
shown to compromise complex formation activities
of CTBP1 on its property as a substrate for CAPN3
was also examined. Except for the mutation A52E,
these mutations altered the susceptibility of CTBP1
to CAPN3-mediated proteolysis while the decrease
in the amount of the proteolyzed fragment was
observed.
These results suggest that PLEIAD has at least
two functions mediated by different regions of the
molecule: the N-terminal region recruits CTBP1, a
substrate for CAPN3, and the C-terminal region is
involved in suppressing CAPN3's protease activity.
CTBP1 is also a substrate for conventional
calpains
To obtain insight into the role of calpains in the
proteolysis of CTBP1, we examined the proteolysis
of recombinant CTBP1 by recombinant conventional
calpains in vitro. CTBP1 was proteolyzed by
CAPN1 + CAPNS1 (also called μ-calpain, abbrevi-
ated as “CAPN1/S1” in Fig. 5a, lanes 3 and 4) and
CAPN2/S1 (m-calpain; data not shown). The spec-
ificity of the reaction was shown by the suppression
2962 PLEIAD/SIMC1/C5orf25, a Regulator for CAPN3of most of the proteolysis in the presence of
calpastatin (Fig. 5a, lane 5) or in the absence of
Ca2+ (lane 6). In parallel, reactions carried out in the(a)
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2963PLEIAD/SIMC1/C5orf25, a Regulator for CAPN3fragments. With N99% confidence, four peptides
were identified in the [+Ca2+] sample [Fig. 5b, (i) to
(iv)], two of which [Fig. 5b, (iii) and (iv)] were also
detectable in the [−Ca2+] sample. These findings
suggested that CTBP1 is cleaved at the N-termini of
G376 (Fig. 5b, [1]) and V388 (Fig. 5b, [2]) by
CAPN1 + S1 in the presence of Ca2+.
As mentioned above, CAPN3 proteolyzed CTBP1
at Gly410 at the N-terminus (Fig. 4c). Therefore, the
same position detected here (Fig. 5b, [4]) is very
likely to be a proteolytic site for conventional calpain,
as well. However, the possibility of nonspecific
proteolysis by non-calpain contaminating proteases
cannot be completely eliminated due to the detection
of the same peptides in the [−Ca2+] sample,
although their intensity was much lower than that
detected in the [+Ca2+] sample. In addition, analysis
of the CTBP1 sequence using our cleavage site
predictor for calpain36 recognized the three positions
[1], [2], and [4] by three different algorithms (Fig. 5c).
Collectively, these data indicate that sites [1], [2],
and [4] are probably cleaved by conventional calpain
and that site [3] may represent nonspecific proteol-
ysis. It remains unclear whether cleavage sites [1]
and [2] are recognized by CAPN3. However, the
small amount of a fragment detectable above the
major proteolyzed fragments in Fig. 4b (lanes 2 and
4, gray arrow) may indicate that the cleavage by
CAPN3 also occurred at sites [1] and/or [2].
PLEIAD may regulate CAPN3 that is not bound
to sarcomere components
To gain further insight into PLEIAD's physiological
relevance, we examined PLEIAD's cellular localiza-
tion in primary cultures of chick skeletal myotubes
expressing EGFP-hPLEIADf (Fig. 6). In total, 200
transfected cells expressing EGFP-hPLEIADf were
compared to 150 cells expressing EGFP alone. In
~10% of the transfected cells, hPLEIADf was
localized in a striated pattern within the sarcomeric
I band, but most cells showed diffuse cytoplasmic
staining (Fig. 6d, inset: see GFP staining, i.e.,
hPLEIADf, on each side of the Z-line, marked byFig. 3. The N-terminal region of PLEIAD interacts with CTB
identified CTBP1 as a binding protein for PLEIAD. The fun
previously validated missense mutants, four different mutants
were selected. The mouse sequence has an insertion of 1 aa
Horizontal bar indicates the antigenic polypeptides for anti-CT
ex4term, was sufficient for the interaction (3D and 4D), while the
and f, failed to undergo detectable interaction (5D). Two differ
negative effect on its interaction with PLEIAD (2F to 4F and 2
CTBP1 was examined using wheat-germ cell-free expressio
components for translation reaction, solution of CTBP1 protein
were mixed and subjected to immunoprecipitation using anti
coimmunoprecipitated with CAPN3:CS (lanes 5 and 7, CBB a
(anti-CTBP1). Numbers in parentheses indicate the perce
precipitation of CTBP1 during translation reaction was not detstaining for α-actinin). These results suggested that
PLEIAD's primary target may be a population of
CAPN3 that exists in the cytosol. For unknown
reasons, it was more difficult to express EGFP-
hPLEIADa as efficiently as EGFP-hPLEIADf. These
two isoforms also showed different expression/
degradation patterns in COS7 cells, independent of
CAPN3's protease activity (Fig. 1d, lanes 4 and 5
and lanes 8 and 9, anti-FLAG). Such a difference
might be enhanced in skeletal myotubes, resulting in
a more severe degradation of hPLEIADa than of
hPLEIADf.Discussion
The unique properties of CAPN3 include its very
rapid and exhaustive autolysis in vitro in protein
expression systems and nonmuscle cultured cells
(CAPN3 is stable in primary skm cells21) and its
dependence on both Na+ and Ca2+ for its
activation.32 These phenomena have been studied
mostly with respect to causative factors; for example,
it has been shown that CAPN3-specific insertion
sequences, IS1 and IS2, are required for autolytic
events.21,35,37 In contrast, it is unclear why CAPN3
remains intact in skm cells without undergoing
autolysis. Surprisingly, in CAPN3:CS knockin mice,
in which the endogenous wild-type CAPN3 (CAPN3:
WT) is replaced by a protease-inactive mutant
CAPN3:CS, the amount of CAPN3:CS protein
detected in the skm cells and tissues is the same
as in wild-type mice. Moreover, the presence of
intact CAPN3 protein, that is, of either WT or the CS
mutant, is sufficient to fulfill its function at the triad
region, even when its protease activity is
lacking.18,19 These findings strongly suggest that,
in addition to connectin/titin, which is a strong
candidate for stabilizing and regulating CAPN3 in
muscle sarcomeres, another mechanism is present
to stabilize CAPN3, especially when it is not
associated with sarcomeres.
As an approach to understanding the mechanism
by which CAPN3 conducts diverse functions inP1. (a) YTH screening using a human skm cDNA library
ctional annotation for human CTBP1 is shown. Among
that compromised complex formation activities of CTBP1
at the C-terminal region and therefore consists of 441 aa.
BP1. (b) The N-terminal region, hPLEIAD-N or hPLEIADf:
C-terminal region, hPLEIAD-C, shared by both hPLEIADa
ent mutations in PXDLS-binding domain of CTB1 showed
H to 4H). (c) Complex formation of CAPN3, PLEIAD, and
n system. In addition to the layer of mRNA and other
was set on the bottom of the tube. After translation, layers
-CAPN3 antibody. (d) Both PLEIADa and PLEIADf were
nd anti-His). In these samples, CTBP1 was also detected
ntage of the total amount. Nonspecific degradation or
ected (data not shown).
Fig. 4. CTBP1, a binding protein for PLEIAD, is a potential CAPN3 substrate. (a) Triple-tagged CTBP1 (MYC-CTBP1-
EGFP-FLAG) expressed in COS7 cells was proteolyzed when CAPN3:WT was coexpressed (lane 1). This CTBP1
construct was susceptible to proteolysis (lane 2), but the difference between lanes 1 and 2 was still significant. In the cells
expressing CAPN3:WT, the endogenous CTBP1 was undetectable (compare lanes 3 and 4). (b) Proteolysis of the CTBP1
construct was also observed in COS7 cells coexpressing mouse CAPN3:ΔIS1 (lane 4, anti-FLAG); CAPN3:ΔIS1 is a
splicing variant that shows protease activity comparable to that of WT but lacks the autolytic sites encoded by exon 6. The
C-terminal proteolyzed fragment of the CTBP1 construct was immunoprecipitated by anti-FLAG, and its N-terminal
sequence was determined. (c) In cultured myotubes, the activation of CAPN3 by ouabain treatment did not cause
significant proteolysis of endogenous CTBP1 protein (lane 2). (d) Proteolysis of CTBP1 by CAPN3 depends on functional
structure of CTBP1. Four different CTBP1 mutants (see Fig. 3a) were coexpressed with CAPN3:WT or CAPN3:CS. In
contrast to wild-type CTBP1, three of the mutants showed altered susceptibility to proteolysis (lanes 5, 7, and 9). For the
mutant A52E, no significant change was observed (lane 3). Closed and open arrowheads indicate the full-length and
autolytic fragments of CAPN3, respectively, detected byWestern blotting using an anti-CAPN3 antibody. Gray arrowheads
indicate endogenous CTBP1. Closed, open, and gray arrows indicate the full-length, the main, and the minor proteolyzed
fragment of the CTBP1 construct expressed in COS7 cells, respectively.
2964 PLEIAD/SIMC1/C5orf25, a Regulator for CAPN3different subcellular compartments, we sought to
identify molecular interactions that affect its protease
activity. Here, we showed that PLEIAD/SIMC1/C5orf25, a novel CAPN3-binding protein, moderates
the protease activity of CAPN3 and possesses the
potential to function as a scaffold protein.
Fig. 5. Proteolysis of CTBP1 by classical calpain, μ-calpain (CAPN1/S1), revealed additional cleavage sites. (a)
Recombinant CTBP1 protein was incubated under the conditions indicated at the top. CTBP1 was proteolyzed by CAPN1/
S1 in the presence of Ca2+ (lane 4), and this reaction was inhibited by calpastatin peptide (lane 5). Peptide fractions
generated in the presence (lane 4, [+Ca2+]) or in the absence (lane 6, [−Ca2+]) of Ca2+ were further analyzed by mass
spectrometry. Closed and open arrowheads indicate the full-length and the main proteolyzed fragment of recombinant
CTBP1. Closed and open arrows indicate CAPN1 and recombinant calpastatin domain 1. *, unidentified signal. (b) Four
peptides were identified in the [+Ca2+] sample [horizontal bars (i) to (iv)], and four cleavage sites by CAPN1/S1 at the C-
terminus of CTBP1 were revealed (vertical arrowheads, [1] to [4]). Two sequences, (iii) and (iv), were also detected in the
[−Ca2+] sample, suggesting that the peptide bonds at positions [3] and [4] have a propensity to be hydrolyzed. (c) Calpain
cleavage sites in CTBP1 were predicted using our predictor available at http://www.calpain.org. Three cleavage sites, [1],
[2], and [4], coincided with those predicted by at least three different algorithms. +, predicted; −, not predicted; **,
biochemically identified as the cleavage site for CAPN3 [Fig. 4, (c)].
2965PLEIAD/SIMC1/C5orf25, a Regulator for CAPN3PLEIAD is a novel CAPN3-regulating protein
So far, this is the first report on the functional
properties of PLEIAD. In addition, we have shown
that, in skm, a Pleiad transcript that lacks exons 2
and 3 is the predominant variant. Notably, this
PLEIAD variant has not been identified in other
human tissues, such as brain or testis, strongly
suggesting that it is a low-abundance isoform that
may be muscle specific. Unlike CAPN3, the ubiqui-tous expression of PLEIAD has been shown in
databases at both transcript† and protein levels.‡
The differential expression of PLEIAD has been
detected by the transcriptional profiling of many
diseases, including muscular dystrophies,38 but it is
not clear if these changes are related to CAPN3's
functions. YTH screening revealed that PLEIAD also
interacts with CTBP1, and it may interact with other
cytosolic and/or cytoskeletal proteins. Therefore,
further studies are necessary to address the
anti-α-actinin anti-GFP
EGFP-alone
EGFP-hPLEIADf
(a)
(c)
(b)
(d)
10 μm
Fig. 6. PLEIAD shows diffuse cytoplasmic localization in skeletal myotubes. Localization of expressed EGFP-
hPLEIADf was examined in cultured chick skeletal myotubes. Cells were stained with anti-sarcomeric α-actinin (a and d)
and anti-GFP antibodies (b and d). The primary localization of hPLEIADf was diffusely cytoplasmic (data not shown).
Occasionally, in about 10% of transfected cells, EGFP-hPLEIADf was localized in a striated pattern within the sarcomeric I
band, on each side of the Z-line (d, inset). Arrow and arrowheads indicate a Z-line labeled by α-actinin and EGFP-
hPLEIADf, respectively. The scale bar represents 10 μm.
2966 PLEIAD/SIMC1/C5orf25, a Regulator for CAPN3possibility that PLEIAD has many functional links to
other proteins, not only in skm but also in other
tissues. The two recently identified tandem SUMO-
interacting motifs at PLEIAD's N-terminus also
indicate its potential roles in signaling pathways
regulated by sumoylation. Another interesting finding
is that humans have one PLEIAD pseudogene
(PLEIAD-ps1, originally called LOC202181) close
to PLEIAD (5q35.3 and 5q35.2, respectively).
From the viewpoint of molecular evolution, it is
noteworthy that the C-terminal region of PLEIAD,
which is responsible for the CAPN3 suppressor
effect, is significantly conserved from human to fish
and that CAPN3 is also evolutionarily conserved
among vertebrates. There are, however, some
inconsistencies: (1) The mouse ortholog, mPLEIAD,
is much larger than the orthologs found in most
mammals. The observed increase in protein size is
caused by the insertion of a highly repetitive
sequence in mouse exon 2, which corresponds to
human exon 4. (2) At least in human and in mouse,
one splicing variant has a structurally identical exon
composition, and this variant lacks exon 4 in the
human and exon 2 in the mouse [Figs. 1b, (c:Δex2-4)
and 2c, (b)], respectively. Although these variants
were not detected in skm in our hands, the identified
transcripts in lower vertebrates show more similarity
to these variants and lack the N-terminal region. (3)
The ortholog found in marsupials, Monodelphisdomestica (opossum), lacks the sequence corre-
sponding to the Pro-rich region in hPLEIAD [Fig. 2a,
(4)].39 It is a serious concern that potential sequenc-
ing errors in databases could result in our misinter-
pretation of the structure of PLEIAD homologs, while
our sequence analyses suggested that the PLEIAD
gene has been a target of evolutionary modification
by repetitive sequences, such as transposable
elements.40 These findings complicate our conclu-
sion regarding the canonical functional structure of
PLEIAD. In particular, the second point described
above argues against the simple explanation that the
N-terminal region of PLEIAD recruits substrates
while its C-terminal region suppresses the CAPN3
protease activity. It is possible that the CAPN3-
suppressing activity was conserved during verte-
brate evolution, whereas the functions of the N-
terminal parts diverged. It is nonetheless tempting to
speculate that the N-terminal substrate scaffold
function is applicable to the PLEIAD orthologs
found in largemammals such as human and bovines.
Relevance of the C-terminal cleavage in
CTBP1 functions
Our biochemical evidence indicated that CTBP1 is
a good substrate for calpains including CAPN3.
CTBP1 has multiple functions in both the nucleus
and the cytoplasm.30,31,41,42 In particular, its function
2967PLEIAD/SIMC1/C5orf25, a Regulator for CAPN3as a nuclear transcriptional regulator has been well
studied.43–45 CTBP1's regulation is important for
proper proliferation and differentiation.45–49 For
example, the down-regulation of CTBP1 at the
protein level, which is catalyzed by the ubiquitin-
proteasome pathway,50 counteracts oncogenic
gene expression.51 In addition, phosphorylation
and sumoylation at the C-terminus of CTBP1 exert
regulatory effects.42 Notably, CTBP1's cleavage by
calpains removes these modification sites, suggest-
ing that calpains also participate in the regulation of
CTBP1, although we could not detect this cleavage
in vivo.
The function of CTBP1 in skm remains unclear;
therefore, it is difficult to speculate about what the
outcomes of CAPN3-mediated CTBP1 proteolysis
are. One possibility is that the regulation of CTBP1
by CAPN3 is functionally analogous to a previously
proposed role of CAPN3 in down-regulating β-
catenin in skm.13 Since CTBP1 itself is capable of
carrying out multi-directional functions, its stage-
specific regulation may be involved in skm cell fusion
and development into myotubes.
For the interaction between CTBP1 and PLEIAD, it
was suggested that PXDLS-binding site on CTBP1
is involved at the level of YTH assay, and further
analyses are required to evaluate its biological
significance. It was also suggested that CAPN3
recognizes the structure of CTBP1 relevant for its
PXDLS binding and NAD(H) binding. However, there
is a possibility that the selected CTBP1 mutations
have too strong effect on the overall structure of the
molecule and the essential structure of CTBP1 as a
substrate for calpain warrants further investigation.
Possible link between the CAPN3–PLEIAD and
CAPN3–connectin/titin interactions
We previously proposed that the N2A region of
connectin/titin supports the functions of CAPN3 by
stabilizing CAPN3 while it recruits MARPs (muscle
ankyrin repeat proteins) as substrates for CAPN3.
Such a model is physically possible for connectin/
titin, since it is located in sarcomeres, which are
mostly composed of extension-competent struc-
tures, such as immunoglobulin motifs and fibronectin
type III-like domains. From the primary sequence of
PLEIAD, it is not clear if a robust structural change
occurs upon its interaction with CAPN3 and/or
CTBP1. Still, it is worth noting that the C-terminal
functional region of PLEIAD has no defined structure
and/or motif. The specificity and efficiency of
calpastatin, a specific inhibitory protein for classical
calpains except CAPN3, relies on its unstructured
nature; it is classified as an intrinsically unstructured/
disordered protein52; calpastatin binds close to, but
loops out into, the side opposite calpain's active site,
escaping cleavage by the calpain.53,54 Although
there is not a strong sequence similarity betweenPLEIAD and calpastatin, it is possible that PLEIAD
functions in an analogous manner. We also hypoth-
esize that the N-terminal region of PLEIAD is
involved in the regulation of CAPN3 autolysis by
increasing the affinity of the molecule to the full-
length, pre-autolyzed form of CAPN3 but is suscep-
tible to protease activity of CAPN3. On the other
hand, the C-terminal region of PLEIAD is resistant to
protease activity of CAPN3 but has lower ability to
interact with CAPN3 by its own.
We sought to detect endogenous mPLEIAD in
mouse tissues using two commercially available
anti-hPLEIAD antibodies. These antibodies did not
yield consistent results; thus, we suspended our
analysis of mouse PLEIAD localization during the
preparation of this manuscript. Instead, we used an
alternative approach, the expression of hPLEIAD in
chicken primary cultured skeletal myotubes. The
localization of expressed hPLEIADf (see Fig. 6)
showed that this new regulator of CAPN3 is primarily
distributed diffusely in the cytoplasm. At the same
time, the occasional localization of hPLEIADf within
the sarcomeric I-band region raises the intriguing
possibility that connectin/titin and PLEIAD cooperate
as CAPN3 regulators. Further investigation of the
spatiotemporal expression of the PLEIAD protein in
skm is required in order to address this issue.
In this study, a novel protein–protein interaction
that is capable of regulating CAPN3 in the cytoplasm
as well as in the sarcomere was shown. Along with
the identification of possible CAPN3 functions in
different cellular compartments, it has been un-
known how CAPN3 avoids autolytic degradation
while it is translocated. We anticipate that the
present study will serve as a good starting point
toward understanding how CAPN3 conducts its
multiple functions. It is likely that there are other
interacting molecules relevant to CAPN3's functions
that are yet to be discovered.Materials and Methods
Experimental animals
All procedures used for experimental animals were
approved by the Experimental Animal Care and Use
Committee of Tokyo Metropolitan Institute of Medical
Science, and the animals and related materials were
treated in accordance with the committee's guidelines.
cDNA constructs
The cDNA clone for PLEIAD/C5orf25, which was origi-
nally purchased fromRessourcenzentrumPrimärdatenbank
(German Science Centre for Genome Research), is now
available from Source BioScience (IRATp970H0629D).
The cDNAs for human CAPN3 and mouse CAPN3Δ1
were subcloned into the pSRD expression vector for
2968 PLEIAD/SIMC1/C5orf25, a Regulator for CAPN3protein expression in mammalian cells, as described
previously.25,35 These cDNAs were also expressed as N-
terminal FLAG-tagged or MYC-tagged proteins using the
pSRD or pcDNA3.1 expression vector (Invitrogen, Grand
Island, NY).55 The pEGFP-C1 expression vector was also
used. For the YTH assay, the pAS2-1c25 and pACT2
expression vectors (U29899; Clontech, Mountain View,
CA) were used. Enzymes used to manipulate recombi-
nant DNA were purchased from Takara Bio (Shiga,
Japan) or New England Biolabs (Ipswich, MA). The
mutations described here were introduced by long PCR
using Pfu-Turbo DNA polymerase, as described
previously.56 All the constructs were verified by DNA
sequencing.
PCR and RT-PCR analyses
Endpoint PCR reactions to detect the expression of
C5orf25 were performed using ExTaq DNA polymerase
(Takara) and the appropriate primer pairs (Fig. 1b and
Table 1). Some PCR products were sequenced for
verification. The human skm cDNA library for YTH
(Clontech) or mouse skm cDNA synthesized from total
RNA was used as a template. Total RNA was prepared
from cultured mouse muscle cells and the quadriceps
femoris of 30-week-old C57BL/6J mice using TRIzol®
Reagent (Invitrogen), according to the manufacturer's
instructions. For RT by PrimeScript® Reverse Transcrip-
tase (Takara), 1.5 μg and 1.1 μg of total RNA from cultured
cells and tissues, respectively, were used per 10-μl
reaction.
Cell culture and protein expression
Protein expression in HEK293 cells was performed as
previously described.28 COS7 cells were grown in
Dulbecco's modified Eagle's medium (Sigma-Aldrich, St.
Louis, MO) supplemented with 10% fetal bovine serum
that had been heat inactivated at 56 °C for 30 min before
use. For recombinant protein expression in COS7 cells,
the plasmid was prepared at a concentration of 1 μg/μl and
transfected using TransIT®-LT1 (Mirus Bio LLC, Madison,
WI). As a standard, 2–4 μg of plasmid plus a 3× volume of
transfection reagent were used per 1.5 × 105 cells plated
in 3.5-cm dish, 12–16 h prior to transfection. The cells
were harvested 40–60 h after transfection using ice-cold
phosphate-buffered saline.26
Primary cultures of chick skeletal myotubes were
prepared as described previously.57 Cells used for
immunofluorescence were grown on coverslips coated
with Matrigel™ (BD Biosciences, San Jose, CA) diluted to
0.5 mg/ml in minimum essential medium. Transfection
was performed 12–16 h after plating using Effectene
(Qiagen, Valencia, CA), as previously described.58 Prima-
ry cultures of mouse skm cells were prepared as described
previously.27 Cells were allowed to differentiate for 5 and
10 days and used for total RNA purification and a 2-h
incubation with ouabain, respectively.
In vitro transcription and translation were performed
using a wheat-germ cell-free expression system, accord-
ing to the manufacturer's instructions (CellFree Sciences,
Japan). The mRNAs for each construct were transcribed
separately. The translation reaction was carried out at16 °C for 18–20 h without shaking. Two micrograms of
recombinant CTBP1 (1 mg/ml stock solution) was added
to the bottom of 112-μl translation reaction mixture.
Immunoprecipitation
Harvested cells were suspended in lysis buffer [50 mM
Tris–HCl (pH 7.5), 150 mM CsCl, 1 mM ethylenediamine-
tetraacetic acid-KOH (pH 8.0), and 1% Triton X-100]
containing protease inhibitors [1 mM 4-(2-aminoethyl)
benzenesulfonyl fluoride hydrochloride, 0.1 mM leupeptin,
10 μg/ml aprotinin, and 10 mM iodoacetamide] and incu-
bated on ice for 30 min with occasional mixing. The
supernatant was collected after centrifugation at 20,630g
at 4 °C for 15 min. Incubation with anti-FLAG M2 affinity
gel (Sigma-Aldrich) and elution of the immunoprecipitated
proteins were performed according to the manufacturer's
instructions using a modified wash buffer [50 mM Tris–HCl
(pH 7.5) and 150 mM CsCl].26 To detect the CAPN3–
PLEIAD interaction, we carried out the incubation for 2–
3 h. When anti-CAPN3 antibody was used for immuno-
precipitation, the immunocomplex was recovered by
Protein-G Sepharose (GE Healthcare). The eluate was
subjected to SDS-PAGE andWestern blot analysis. For N-
terminal sequencing, the immunoprecipitated proteins
were blotted onto a ProBlott membrane (Applied Biosys-
tems, Carlsbad, CA) after SDS-PAGE. The target protein
bands were visualized by CBB G-250 staining, excised,
and submitted to APRO Science Institute Inc. (Tokushima,
Japan) for sequence analysis.Western blot analysis
Proteins were separated by SDS-PAGE and transferred
onto polyvinylidene fluoride membranes (Millipore, Bed-
ford, MA). The membranes were probed with the appro-
priate primary antibodies and horseradish-peroxidase-
coupled secondary antibodies (Nichirei, Tokyo, Japan)
followed by visualization using a POD immunostaining kit
(Wako, Osaka, Japan) or SuperSignal® West Pico
Chemiluminescent Substrate (Pierce, Rockford, IL).26
Scanned images were processed for presentation using
Adobe Photoshop CS6 (Adobe Systems, San Jose, CA).
Immunofluorescence analysis
Immunofluorescence microscopy was performed as
described previously.58 At 4–5 days after transfection,
the cells were incubated in relaxing buffer [150 mM KCl,
5 mM MgCl2, 10 mM 3-(N-morpholino) propanesulfonic
acid (pH 7.4), 1 mM ethylene glycol bis(β-aminoethyl
ether) N,N′-tetraacetic acid, and 4 mM ATP] for 15 min,
followed by fixation using 2% formaldehyde in relaxing
buffer for 15 min. The primary and secondary antibodies
were used at the concentrations described in Antibodies.
Coverslips were mounted onto slides with Aqua Poly/
Mount (Polysciences, Warrington, PA), and the samples
were analyzed on an Axiovert microscope (Zeiss, Ober-
kochen, Germany) using 63× (NA 1.4) or 100× (NA 1.3)
objectives. The cells were also analyzed using a Deltavi-
sion RT system (Applied Precision, Issaquah, WA) with an
inverted microscope (IS70; Olympus, Tokyo, Japan), a
2969PLEIAD/SIMC1/C5orf25, a Regulator for CAPN3100× (NA 1.3) objective, and a charge-coupled device
camera (CoolSNAP HQ; Photometrics, Huntington Beach,
CA). The images were deconvolved using SoftWoRx 3.5.1
software (Applied Precision) and processed for presenta-
tion using Adobe Photoshop CS6 (Adobe Systems).
Antibodies
The antibodies used in this study include anti-FLAG
mouse monoclonal (1:1000, M2; Stratagene, La Jolla, CA),
anti-MYC mouse monoclonal (1:1000, 9E10; Develop-
mental Studies Hybridoma Bank), anti-calpastatin mouse
monoclonal (1:1000, PI-11; American Type Culture Col-
lection), anti-CTBP1 mouse monoclonal (1:1000, 3/CtBP1;
BD Transduction Laboratories™), anti-α-actinin mouse
monoclonal (1:2000, EA-53; Sigma-Aldrich), anti-GFP
rabbit polyclonal (1:2000; Abcam, Cambridge, MA), anti-
CAPN3 goat polyclonal (1:1000; Cosmo Bio, Tokyo,
Japan), anti-His mouse monoclonal (1:2000; Novagen),
and anti-proteolyzed fodrin (anti-GMMPR) rabbit polyclon-
al (1:1000, anti-GMMPR) antibodies.26,32 As secondary
antibodies, Alexa Fluor 488-conjugated goat anti-rabbit
IgG (1:1000; Invitrogen) and Texas Red-conjugated
donkey anti-mouse IgG (1:600; Jackson Immunoresearch
Laboratories, West Grove, PA) antibodies were used.
Protein identification by mass spectrometry
The FLAG-immunoprecipitates from HEK293 cells were
analyzed using direct nanoflow liquid chromatography
coupled with tandem mass spectrometry.28 To identify the
peptide sequence generated during the in vitro proteolysis
of CTBP1, we desalted the reaction solution using ZipTip®
Pipette Tips (Millipore), and tandem mass spectrometry
spectra were acquired by a 4800 MALDI TOF/TOF™
analyzer (AB SCIEX, Framingham, MA). Data were
analyzed by Protein Pilot™ software (version 4.5) (AB
SCIEX).
Calpain cleavage assay in vitro
Two hundred nanograms of recombinant human
CTBP1 (ProSpec, Ness Ziona, Israel) was incubated
with 25 ng of recombinant human CAPN1/S1 (μ-calpain)
(BioVision, Milpitas, CA) in 10 μl of incubation buffer
[20 mM Tris–HCl (pH 8.0), 1 mM ethylenediaminetetraa-
cetic acid-KOH (pH 8.0), and 1 mM DTT] with or without
10 mM CaCl2 at 30 °C for 10 and 30 min. Where
indicated, recombinant human calpastatin domain I
(Takara) was added to a concentration of 29 mM. The
reaction was stopped by the addition of SDS sample
buffer, and the sample was subjected to SDS-PAGE
followed by CBB G-250 staining.
YTH assay
Proteins interacting with C5orf25 were screened as
previously reported22 using Saccharomyces cerevisiae
strain AH109. The full-length PLEIAD cDNA cloned into
pAS2-1c was coexpressed in the yeast with approxi-
mately 1.3 × 106 of a human skm cDNA library in thepGAD424 vector (Clontech). The plasmids were rescued
from colonies grown on SD medium that lacked Leu, Trp,
His, and Ade (SD-LWHA) and were sequenced. The
rescued plasmids were retransformed with a series of
PLEIAD mutants using the Fast™-Yeast Transformation
Kit (G-Biosciences/Genotech, St. Louis, MO), according
to the manufacturer's instructions. Cotransformants were
selected on SD-LW plates, and the expressions of
reporter genes were assessed by growth on SD-LWHA
plates.Sequence analysis
Sequence data were retrieved from the NCBI§ and
Ensembl∥ databases. The sequences from UniProtKB¶
were also used to check the consistency. BLAST searches
were performed with psi-BLAST and BLAST-p and
tBLAST-n versus the nonredundant protein or nucleotide
databases. For phylogenetic analysis, sequences were
aligned using MAFFTa59 and converted to an unrooted
tree diagram after manual inspection. The identity and
similarity of aligned sequences were calculated using
Genetyx (version 11) (Genetyx Co., Tokyo, Japan).
Sequence repeats were identified with RADAR,b60 and
designated sequences were aligned using MAFFT and
Genetyx. To predict calpain cleavage sites, we analyzed
the protein sequences with an online cleavage site
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